Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide

British Journal of Pharmacology

Volumn 165, Issue 6, 2012, Pages 1877-1890

  Buenestado, A ^a   Grassin Delyle, S ^a   Guitard, F ^a   Naline, E ^a   Faisy, C ^a,b   Israel Biet D ^c   Sage, E ^a   Bellamy, J F ^d   Tenor, H ^e   Devillier, P ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Thoracic Surgery   (France)

^e NONE   (Germany)

Author keywords

chemokines; LPS; lung macrophages; roflumilast; TNF

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CXCL1 CHEMOKINE; CYCLOOXYGENASE 2; DRUG METABOLITE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INDOMETACIN; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E; PROSTAGLANDIN E2; PROSTAGLANDIN E4; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL FREE SYSTEM; CELL ISOLATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; ISOLATED LUNG; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

AMINOPYRIDINES; BENZAMIDES; CELLS, CULTURED; CHEMOKINES; CYCLOPROPANES; DINOPROSTONE; EPOPROSTENOL; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857485173     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01667.x     Document Type: Article

References (67)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Aronoff DM, Peres CM, Serezani CH, Ballinger MN, Carstens JK, Coleman N, et al,. (2007). Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-receptor binding specificities. J Immunol 178: 1628-1634.
3. Au BT, Teixeira MM, Collins PD, Williams TJ, (1998). Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol. Br J Pharmacol 123: 1260-1266.
4. Banner KH, Hoult JR, Taylor MN, Landells LJ, Page CP, (1999). Possible Contribution of Prostaglandin E2 to the antiproliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells. Biochem Pharmacol 58: 1487-1495.
5. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, et al,. (2004). Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 287: L332-L343.
6. Barnes PJ, (2004). Alveolar macrophages as orchestrators of COPD. COPD 1: 59-70.
7. Barnes PJ, (2009). The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 41: 631-638.
8. Bauer AC, Schwabe U, (1980). An improved assay of cyclic 3€,5€-nucleotide phosphodiesterases with QAE-Sephadex columns. Naunyn Schmiedebergs Arch Pharmacol 311: 193-198.
9. Bender AT, Beavo JA, (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
10. Bethke TD, Bohmer GM, Hermann R, Hauns B, Fux R, Morike K, et al,. (2007). Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 47: 26-36.
11. Braber S, Henricks PA, Nijkamp FP, Kraneveld AD, Folkerts G, (2010). Inflammatory changes in the airways of mice caused by cigarette smoke exposure are only partially reversed after smoking cessation. Respir Res 11: 99.
12. Bracke KR, D'hulst AI, Maes T, Demedts IK, Moerloose KB, Kuziel WA, et al,. (2007). Cigarette smoke-induced pulmonary inflammation, but not airway remodelling, is attenuated in chemokine receptor 5-deficient mice. Clin Exp Allergy 37: 1467-1479.
13. Bryn T, Mahic M, Enserink JM, Schwede F, Aandahl EM, Tasken K, (2006). The cyclic AMP-Epac1-Rap1 pathway is dissociated from regulation of effector functions in monocytes but acquires immunoregulatory function in mature macrophages. J Immunol 176: 7361-7370.
14. Buenestado A, Grassin Delyle S, Arnould I, Besnard F, Naline E, Blouquit-Laye S, et al,. (2010). The role of adenosine receptors in regulating production of tumour necrosis factor-alpha and chemokines by human lung macrophages. Br J Pharmacol 159: 1304-1311.
15. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, (2009). Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374: 685-694.
16. Capelli A, Di Stefano A, Gnemmi I, Balbo P, Cerutti CG, Balbi B, et al,. (1999). Increased MCP-1 and MIP-1beta in bronchoalveolar lavage fluid of chronic bronchitics. Eur Respir J 14: 160-165.
17. Costa C, Rufino R, Traves SL, Lapa ESJR, Barnes PJ, Donnelly LE, (2008). CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 133: 26-33.
18. Delgado M, Ganea D, (2001). Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol 167: 966-975.
19. Donnelly LE, Tudhope SJ, Fenwick PS, Barnes PJ, (2010). Effects of formoterol and salmeterol on cytokine release from monocyte-derived macrophages. Eur Respir J 36: 178-186.
20. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, et al,. (2009). Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374: 695-703.
21. Fan Chung K, (2006). Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol 533: 110-117.
22. Freeman CM, Curtis JL, Chensue SW, (2007). CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. Am J Pathol 171: 767-776.
23. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A, (1997). In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol 121: 221-231.
24. Giembycz MA, Field SK, (2010). Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 4: 147-158.
25. Grootendorst DC, Gauw SA, Verhoosel RM, Sterk PJ, Hospers JJ, Bredenbroker D, et al,. (2007). Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 62: 1081-1087.
26. Hatzelmann A, Schudt C, (2001). Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297: 267-279.
27. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, et al,. (2010). The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23: 235-256.
28. Hempel SL, Monick MM, Hunninghake GW, (1994). Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J Clin Invest 93: 391-396.
29. Houslay MD, Schafer P, Zhang KY, (2005). Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10: 1503-1519.
30. Jin SL, Conti M, (2002). Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 99: 7628-7633.
31. Jin SL, Lan L, Zoudilova M, Conti M, (2005). Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J Immunol 175: 1523-1531.
32. Kaur M, Holden NS, Wilson SM, Sukkar MB, Chung KF, Barnes PJ, et al,. (2008). Effect of beta2-adrenoceptor agonists and other cAMP-elevating agents on inflammatory gene expression in human ASM cells: a role for protein kinase A. Am J Physiol Lung Cell Mol Physiol 295: L505-L514.
33. Kavelaars A, Van De Pol M, Zijlstra J, Heijnen CJ, (1997). Beta 2-adrenergic activation enhances interleukin-8 production by human monocytes. J Neuroimmunol 77: 211-216.
34. Keatings VM, Collins PD, Scott DM, Barnes PJ, (1996). Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 153: 530-534.
35. Kent LM, Smyth LJ, Plumb J, Clayton CL, Fox SM, Ray DW, et al,. (2009). Inhibition of lipopolysaccharide-stimulated chronic obstructive pulmonary disease macrophage inflammatory gene expression by dexamethasone and the p38 mitogen-activated protein kinase inhibitor N-cyano-N'-(2-{[8-(2,6- difluorophenyl)-4-(4-fluoro-2-methylphenyl)-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidin-2-yl]amino}ethyl)guanidine (SB706504). J Pharmacol Exp Ther 328: 458-468.
36. Kimata M, Shichijo M, Daikoku M, Inagaki N, Mori H, Nagai H, (1998). Pharmacological modulation of LPS-induced MIP-1 alpha production by peripheral blood mononuclear cells. Pharmacology 56: 230-236.
37. Klein T, Shephard P, Kleinert H, Komhoff M, (2007). Regulation of cyclooxygenase-2 expression by cyclic AMP. Biochim Biophys Acta 1773: 1605-1618.
38. Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H, Kim HJ, et al,. (2002). PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels. Am J Respir Cell Mol Biol 26: 694-701.
39. Lahu G, Hunnemeyer A, Diletti E, Elmlinger M, Ruth P, Zech K, et al,. (2010). Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model. Clin Pharmacokinet 49: 589-606.
40. Linden A, (1996). Increased interleukin-8 release by beta-adrenoceptor activation in human transformed bronchial epithelial cells. Br J Pharmacol 119: 402-406.
41. Livak KJ, Schmittgen TD, (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
42. Ma D, Wu P, Egan RW, Billah MM, Wang P, (1999). Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol 55: 50-57.
43. Martorana PA, Lunghi B, Lucattelli M, De Cunto G, Beume R, Lungarella G, (2008). Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice. BMC Pulm Med 8: 17.
44. Montuschi P, Kharitonov SA, Ciabattoni G, Barnes PJ, (2003). Exhaled leukotrienes and prostaglandins in COPD. Thorax 58: 585-588.
45. Muhl H, Chang JH, Huwiler A, Bosmann M, Paulukat J, Ninic R, et al,. (2000). Nitric oxide augments release of chemokines from monocytic U937 cells: modulation by anti-inflammatory pathways. Free Radic Biol Med 29: 969-980.
46. Nie L, Xiang R, Zhou W, Lu B, Cheng D, Gao J, (2008). Attenuation of acute lung inflammation induced by cigarette smoke in CXCR3 knockout mice. Respir Res 9: 82.
47. Peters-Golden M, (2004). The alveolar macrophage: the forgotten cell in asthma. Am J Respir Cell Mol Biol 31: 3-7.
48. Profita M, Sala A, Bonanno A, Riccobono L, Ferraro M, La Grutta S, et al,. (2010). Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products. Am J Physiol Lung Cell Mol Physiol 298: L261-L269.
49. Ratcliffe MJ, Walding A, Shelton PA, Flaherty A, Dougall IG, (2007). Activation of E-prostanoid4 and E-prostanoid2 receptors inhibits TNF-alpha release from human alveolar macrophages. Eur Respir J 29: 986-994.
50. Raychaudhuri B, Malur A, Bonfield TL, Abraham S, Schilz RJ, Farver CF, et al,. (2002). The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages. J Biol Chem 277: 33344-33348.
51. Rouzer CA, Kingsley PJ, Wang H, Zhang H, Morrow JD, Dey SK, et al,. (2004). Cyclooxygenase-1-dependent prostaglandin synthesis modulates tumor necrosis factor-alpha secretion in lipopolysaccharide-challenged murine resident peritoneal macrophages. J Biol Chem 279: 34256-34268.
52. Sabatini F, Petecchia L, Boero S, Silvestri M, Klar J, Tenor H, et al,. (2010). A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro. Pulm Pharmacol Ther 23: 283-291.
53. Sanz MJ, Cortijo J, Taha MA, Cerda-Nicolas M, Schatton E, Burgbacher B, et al,. (2007). Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Br J Pharmacol 152: 481-492.
54. Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, et al,. (2010). Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol 159: 842-855.
55. Shepherd MC, Baillie GS, Stirling DI, Houslay MD, (2004). Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol 142: 339-351.
56. Slater DM, Astle S, Woodcock N, Chivers JE, De Wit NC, Thornton S, et al,. (2006). Anti-inflammatory and relaxatory effects of prostaglandin E2 in myometrial smooth muscle. Mol Hum Reprod 12: 89-97.
57. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, et al,. (2004). Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl- nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes. Mol Pharmacol 66: 1679-1689.
58. Spina D, (2008). PDE4 inhibitors: current status. Br J Pharmacol 155: 308-315.
59. Takayama K, Garcia-Cardena G, Sukhova GK, Comander J, Gimbrone MA Jr, Libby P, (2002). Prostaglandin E2 suppresses chemokine production in human macrophages through the EP4 receptor. J Biol Chem 277: 44147-44154.
60. Tenor H, Hatzelmann A, Kupferschmidt R, Stanciu L, Djukanovic R, Schudt C, et al,. (1995). Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 25: 625-633.
61. Thompson WJ, Terasaki WL, Epstein PM, Strada SJ, (1979). Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv Cyclic Nucleotide Res 10: 69-92.
62. Togo S, Liu X, Wang X, Sugiura H, Kamio K, Kawasaki S, et al,. (2009). PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol 296: L959-L969.
63. Traves SL, Culpitt SV, Russell RE, Barnes PJ, Donnelly LE, (2002). Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 57: 590-595.
64. Verghese MW, Mcconnell RT, Lenhard JM, Hamacher L, Jin SL, (1995). Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol 47: 1164-1171.
65. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM, (1999). Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 56: 170-174.
66. Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S, et al,. (1997). Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Gen Pharmacol 29: 633-638.
67. Zhong WW, Burke PA, Drotar ME, Chavali SR, Forse RA, (1995). Effects of prostaglandin E2, cholera toxin and 8-bromo-cyclic AMP on lipopolysaccharide- induced gene expression of cytokines in human macrophages. Immunology 84: 446-452.